Characteristics | All included patients (NÂ =Â 200) | Non-progression patients (NÂ =Â 180) | Progression patients (NÂ =Â 20) |
---|---|---|---|
Baseline | |||
 Age (years) | 36.99 ± 11.33 | 36.20 ± 10.42 | 43.93 ± 16.34 |
 Gender: female, n (%) | 113 (56.5) | 100 (55.60) | 13 (64.30) |
 SBP (mm Hg) | 124.33 ± 17.11 | 124.08 ± 16.08 | 126.43 ± 24.99 |
 DBP (mm Hg) | 81.08 ± 11.10 | 81.33 ± 10.89 | 78.93 ± 13.04 |
 SCr (µmol/L) | 89.2 (68.08–121.35) | 88.25 (67.35–117.70) | 108.95 (84.80–139.40) |
 eGFR (mL/min/1.73 m2) | 70.98 (51.91–95.93) | 72.84 (52.93–96.39) | 53.36 (46.55–62.35) |
 BUN (mmol/L) | 5.98 (4.60–7.80) | 5.90 (4.60–7.40) | 6.78 (5.46–8.94) |
 UA (µmol/L) | 363.00 (311.65–427.50) | 359.00 (310.00–422.00) | 380.50 (347.00–436.00) |
 Hb (g/L) | 131.00 (120.00–143.00) | 132.50 (120.00–144.00) | 124.00 (121.00–132.00) |
 ALB (g/L) | 38.20 (34.10–40.80) | 38.40 (34.60–41.10) | 33.75 (30.20–38.60) |
 UPE (g/day) | 2.27 (1.35–3.41) | 2.14 (1.34–3.14) | 3.08 (2.27–3.84) |
 uRBC/HP | 26.20 (8.03–67.48) | 24.10 (7.80–66.55) | 31.00 (12.30–51.70) |
 CKD stage, n (%) | |||
  Stage I | 67 (33.5) | 63 (35.0) | 4 (20.0) |
  Stage II | 60 (30.0) | 57 (31.6) | 3 (15.0) |
  Stage III | 68 (34.0) | 55 (30.6) | 13 (65.0) |
  Stage IV–V | 5 (2.5) | 5 (2.8) | 0 (0) |
  FSGS, n (%) | 112 (56.0) |  |  |
 Renal biopsy Lee’s classification, n (%) | |||
  Grade I | 4 (2.1) | 3 (1.7) | 1 (5.0) |
  Grade II | 4 (2.1) | 2 (1.1) | 2 (10.0) |
  Grade III | 115 (57.4) | 103 (57.2) | 12 (60.0) |
  Grade IV | 68 (34.0) | 65 (36.1) | 3 (15.0) |
  Grade V | 9 (4.3) | 7 (3.9) | 2 (10.0) |
Follow-up | |||
 Remission, n (%) | 160 (80) | 152(84.4) | 8 (40.0) |
 Complete remission, n (%) | 71 (35.4) | 68 (37.8) | 3 (15.0) |
 Partial remission, n (%) | 89 (44.6) | 84 (46.7) | 5 (25.0) |
 Non-response, n (%) | 40 (20.0) | 28 (15.6) | 12 (60.0) |
 Relapse, n (%) | 35 (17.3) | 24 (13.3) | 11 (55.0) |
 Progression, n (%) | 20 (10) |  |  |
 Length of follow-up (months) | 68.33 (43.60–100.67) | 67.33 (42.93–98.77) | 71.42 (38.37–92.83) |
 ALB (g/L) at month 3 | 39.45 (35.80–43.03) | 40.00 (35.90–43.30) | 37.50 (35.00–40.00) |
 ALB (g/L) at month 6 | 41.50 (37.50–44.15) | 42.20 (38.10–45.00) | 36.75 (35.20–40.00) |
 TA-ALB (g/L) | 40.93 (38.05–44.14) | 42.48 (38.75–44.65) | 37.28 (36.40–39.01) |
 SCr (µmol/L) at month 3 | 88.10 (71.60–105.00) | 87.30 (71.60–104.80) | 101.55 (78.80–112.20) |
 SCr (µmol/L) at month 6 | 80.00 (64.70–104.50) | 79.00 (64.70–100.60) | 97.85 (78.00–128.50) |
 TA-SCr (µmol/L) | 85.24 (64.81–106.75) | 83.73 (64.71–103.46) | 99.34 (77.36–111.91) |
 eGFR (mL/min/1.73 m2) at month 3 | 70.34 (56.97–98.72) | 73.67 (58.04–98.72) | 61.98 (48.87–81.43) |
 eGFR (mL/min/1.73 m2) at month 6 | 80.02 (58.05–103.28) | 81.08 (62.52–103.38) | 58.68 (52.57–82.39) |
 TA-eGFR (mL/min/1.73 m2) | 76.93 (58.30–103.33) | 80.61 (59.49–104.98) | 58.74 (52.66–83.32) |
 UPE (g/day) at month 3 | 0.79 (0.36–1.94) | 0.73 (0.36–1.57) | 1.26 (0.60–2.52) |
 UPE (g/day) at month 6 | 0.63 (0.21–1.51) | 0.60 (0.19–1.39) | 1.36 (0.72–2.29) |
 TA-UPE (g/day) | 0.89 (0.51–1.75) | 0.83 (0.49–1.69) | 2.11 (0.82–2.36) |